AMANDA JURLS: Open Payments
NPI 1588092142 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,712 in 100 payments from 15 companies in 2025. Trend: 2023 $1,815 · 2024 $1,765 · 2025 $1,712
Food & beverage: $1,712
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 28 | $259 |
| Alkermes, Inc. | 13 | $239 |
| E.R. Squibb & Sons, L.L.C. | 10 | $215 |
| Janssen Pharmaceuticals, Inc | 10 | $181 |
| Neurocrine BioSciences, Inc. | 8 | $156 |
| Otsuka America Pharmaceutical, Inc. | 7 | $156 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $147 |
| Teva Pharmaceuticals USA, Inc. | 6 | $104 |
| Vanda Pharmaceuticals Inc. | 4 | $93 |
| ABBVIE INC. | 2 | $38 |
Products named: Qelbree, ARISTADA, COBENFY, INVEGA SUSTENNA, INGREZZA, CAPLYTA, ABILIFY ASIMTUFII, FANAPT.
Industry payments across TN — which companies pay providers there.
